Teva Pharmaceutical Industries

Teva Pharmaceutical Industries
Name	Teva Pharmaceutical Industries
Type	Public
Traded as	NYSE: TEVA, TASE: TEVA
Industry	Pharmaceutical industry
Founded	0 1901 in Jerusalem
Founder	Chaim Salomon, Moshe Levin, Yitzhak Elstein
Hq location city	Tel Aviv
Hq location country	Israel
Key people	Richard Francis (President & CEO), Amir Elstein (Chairman)
Products	Generic drugs, Biosimilars, APIs, Specialty medications
Num employees	~37,000 (2023)

Teva Pharmaceutical Industries. It is a global pharmaceutical company headquartered in Tel Aviv, Israel, and is one of the world's largest producers of generic drugs. Founded in Jerusalem in 1901, it has grown through major acquisitions like IVAX, Barr Pharmaceuticals, and Actavis Generics to become a leader in the industry. The company develops, manufactures, and markets a vast portfolio of generic medicines, biosimilars, APIs, and specialty products for central nervous system and respiratory disorders.

History

The company's origins trace back to a small wholesale drug business established in Jerusalem by Chaim Salomon, Moshe Levin, and Yitzhak Elstein. It was formally incorporated in Tel Aviv in 1935 and began local production of aspirin and antiseptics. A pivotal merger with Assia and Zori in the 1970s created a dominant Israeli entity, which later listed on the New York Stock Exchange in 1987. Its global expansion accelerated with the strategic acquisition of IVAX in 2006, Barr Pharmaceuticals in 2008, and the landmark purchase of Actavis Generics from Allergan in 2016, solidifying its position as a generics powerhouse.

Business and operations

The company operates through two main segments: North America and Europe, with significant presence in markets like Germany, the United Kingdom, and Russia. Its extensive global manufacturing network includes major facilities in Israel, Hungary, Croatia, and the Netherlands, producing billions of tablets and capsules annually. Beyond generics, its API division supplies internal needs and external clients, while its specialty medicine unit focuses on innovative treatments for conditions like multiple sclerosis and Huntington's disease. The firm also maintains important R&D centers in West Chester, Pennsylvania and Netanya.

Products and therapeutic areas

Its broad generic portfolio encompasses thousands of approved products, including copies of major drugs like Lipitor and Viagra. In specialty medicines, it markets Copaxone for multiple sclerosis, Austedo for Huntington's disease, and Ajovy for migraine prevention. The respiratory franchise features products like ProAir and QVAR, and it has a growing pipeline of biosimilars targeting complex biologics such as Humira and Avastin. Key therapeutic focuses include oncology, central nervous system disorders, and women's health.

Legal and regulatory issues

The company has faced significant legal challenges, most notably a multibillion-dollar settlement with the U.S. Department of Justice and multiple states in 2016 over allegations related to the marketing of Copaxone and other drugs. It has been a central defendant in widespread litigation concerning the Opioid epidemic in the United States, reaching a national settlement in 2022. It has also confronted numerous Antitrust investigations by the Federal Trade Commission and the European Commission regarding generic drug pricing and market allocation, alongside ongoing patent disputes with rivals like Mylan and Pfizer.

Financial performance

Revenue peaked following the Actavis Generics acquisition but later faced pressure from generic price erosion in the United States and significant debt from that deal. The company executed a major restructuring plan, closing facilities and reducing its global workforce to cut costs. Key financial metrics are closely watched by investors on the NYSE and TASE, with performance heavily influenced by the launch of new generics, the specialty drug portfolio, and progress in reducing its substantial debt load.

Corporate governance and leadership

The board of directors is chaired by Amir Elstein, with Richard Francis serving as President and Chief Executive Officer. Previous leaders who shaped the company's growth include former CEO Erez Vigodman and longtime chairman Phillip Frost. Governance practices adhere to regulations from the Israel Securities Authority and the U.S. Securities and Exchange Commission. The company's major shareholders have historically included entities like Mackenzie Financial and the Dankner family.

Category:Pharmaceutical companies of Israel Category:Companies listed on the New York Stock Exchange Category:Generic drug manufacturers